` Filed: October 14, 2016
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`IBG LLC; INTERACTIVE BROKERS LLC;
`TRADESTATION GROUP, INC.; TRADESTATION SECURITIES, INC.;
`TRADESTATION TECHNOLOGIES, INC.;
`and IBFX, INC.
`
`Petitioners
`v.
`
`
`
`
`
` TRADING TECHNOLOGIES INTERNATIONAL, INC.
`
`Patent Owner
`_________________
`Case CBM2015-00179
`U.S. Patent 7,533,056
`
`
`
`
`
`
`
`
`
`
`REPLY IN SUPPORT OF PATENT OWNER’S MOTION TO
` EXCLUDE UNDER 37 C.F.R. 42.64(C)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`TABLE OF CONTENTS
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`I. TSE has not been authenticated under FRE 901. ............................................ 1
`A. TT does not concede that the 2005 Kawashima deposition
`transcript is admissible. ................................................................................... 1
`B. Whether or not the 2005 Kawashima deposition transcript is
`excluded, Petitioners have not authenticated TSE. ....................................... 3
`i. The 2005 Kawashima deposition transcript does not authenticate
`TSE.
` ....................................................................................................... 3
`ii. TSE is not authenticated under FRE 902(11) or 901(b)(4). .......... 4
`iii. Petitioner’s supplemental evidence does not authenticate TSE. ... 4
`iv. The 2016 Kawashima deposition transcript does not cure the
`authentication issues with TSE. ................................................................... 4
`II. Expert Testimony ................................................................................................ 5
`
`
`
`
`
`ii
`
`
`
`I.
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`
`TSE has not been authenticated under FRE 901.
`A. TT does not concede that the 2005 Kawashima deposition transcript
`is admissible.
`
`TT’s evidence from district court litigation and the 2005 Kawashima
`
`deposition transcript should stand or fall together based on mutual hearsay
`
`objections. Indeed, as stated in TT’s motion, “[t]o the extent the Board excludes
`
`any of Patent Owner’s evidence from district court litigation, which it should not,
`
`the Board should likewise exclude the 2005 Kawashima transcript.” Paper 114 at
`
`6.
`
`The Board must treat Patent Owner’s district court evidence and the 2005
`
`Kawashima transcript in the same way because they differ only in that Patent
`
`Owner exerted greater efforts to obtain better evidence than Petitioners. To the
`
`extent this difference impacts the admissibility of the evidence, it favors admitting
`
`Patent Owner’s evidence, not the 2005 Kawashima transcript. Qualification for the
`
`residual exception to hearsay requires that evidence be more probative on the point
`
`for which it is offered than any other evidence that the proponent can obtain
`
`through reasonable efforts. FRE 807. While Patent Owner exerted significant
`
`efforts to obtain better evidence, Petitioners did not. Accordingly, based on this
`
`difference, to the extent the 2005 Kawashima transcript is treated differently from
`
`Patent Owner’s evidence from district court, the 2005 Kawashima transcript, not
`
`1
`
`
`
`
`Patent Owner’s evidence from district court, should be excluded.
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`Rather than identifying any other differences between the 2005 Kawashima
`
`transcript and Patent Owner’s evidence from district court, Petitioners argue that
`
`Mr. Kawashima’s cross-examination in this proceeding resolves any hearsay
`
`concern. This does not differentiate the Kawashima 2005 deposition transcript
`
`from Patent Owner’s evidence from district court. Petitioners could have likewise
`
`deposed the witnesses on which Patent Owner relies in this proceeding but simply
`
`chose not to do so. The Board’s recent Final Written Decision in Apple Inc. v.
`
`VirnetX Inc. is instructive. IPR2015-00811, Paper 44 at 68-70 (Sep. 8, 2016). In
`
`the Apple case, the Board pointed out that the party challenging the admissibility of
`
`evidence “chose not to seek the opportunity to cross examine the declaration
`
`testimony,” which the Board had defined to include district court trial and
`
`deposition testimony, before explaining why the residual exception of Federal Rule
`
`of Evidence 807 nevertheless rendered everything admissible. Id. at 68-70. The
`
`Board thus recognized that whether or not a party actually cross-examines a
`
`witness in the proceeding is irrelevant to whether other testimony not from the
`
`proceeding is hearsay. See id.
`
`Unable to articulate any difference between the 2005 Kawashima transcript
`
`and Patent Owner’s evidence from district court, Petitioners avoid the issue by
`
`instead discussing burdens of proof. Paper 118 at 3. Given that there are no
`
`2
`
`
`
`
`differences between the 2005 Kawashima transcript and Patent Owner’s evidence
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`from district court that would favor admitting the 2005 Kawashima transcript but
`
`not Patent Owner’s district court evidence, Petitioners cannot meet their burden to
`
`have Patent Owner’s evidence from district court excluded without also
`
`demonstrating that the 2005 Kawashima transcript must be excluded. Accordingly,
`
`to the extent the Board excludes any of Patent Owner’s evidence from district court
`
`litigation, which it should not, the Board should likewise exclude the 2005
`
`Kawashima transcript.
`
`B. Whether or not the 2005 Kawashima deposition transcript is
`excluded, Petitioners have not authenticated TSE.
`
`Nothing in the record proves that Exhibit 1003 (“TSE”) is the specific
`
`document that Petitioners assert was “published in August of 1998 by giving two
`
`copies to each of the about 200 participants in the Tokyo Stock Exchange” and not
`
`some other TSE document. See Paper 9 at 21.
`
`i.
`
`The 2005 Kawashima deposition transcript does not
`authenticate TSE.
`
`As explained in TT’s motion, the 2005 Kawashima transcript raises more
`
`doubt that it resolves. Citing Rosenberg v. Collins, Petitioners argue that TT’s
`
`criticism of the way Mr. Kawashima verified his identification of the TSE manual
`
`does not cut against authenticity in a way supported by law, but Rosenberg relates
`
`to the business record hearsay exception of FRE 803(6), not to whether the
`
`3
`
`
`
`
`document is the particular document allegedly “giv[en]” to “participants in the
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`Tokyo Stock Exchange.” See 624 F.2d 659, 665 (5th Cir.1980). Paper 118 at 5-6.
`
`Accordingly, it has no bearing on whether Mr. Kawashima ever authenticated any
`
`document as being the one allegedly “giv[en]” to the participants.
`
`TSE is not authenticated under FRE 902(11) or 901(b)(4).
`
`ii.
`Whether or not TSE is a business record or appears to be an authentic TSE
`
`document, nothing establishes that it is the document allegedly “giv[en]” to
`
`“participants in the Tokyo Stock Exchange.” Accordingly, it is not self-
`
`authenticated in any way that can establish it is prior art in this proceeding.
`
`Petitioner’s supplemental evidence does not authenticate TSE.
`
`iii.
`Whether or not TSE is in the file history of a U.S. patent has nothing to do
`
`with whether it is the document allegedly “giv[en]” to “participants in the Tokyo
`
`Stock Exchange.” Moreover, “mere submission of an IDS to the USPTO does not
`
`constitute the patent applicant's admission that any reference in the IDS is material
`
`prior art.” Abbott Labs. v. Baxter Pharm. Prod., Inc., 334 F.3d 1274, 1279 (Fed.
`
`Cir. 2003). Petitioner’s evidence “that a party offered the same document [as
`
`Petitioners] in a related district court action” is also irrelevant to whether it is the
`
`document allegedly “giv[en]” to “participants in the Tokyo Stock Exchange.”
`
`iv.
`
`The 2016 Kawashima deposition transcript does not cure the
`authentication issues with TSE.
`
`As an initial matter, Petitioners submit and rely upon new evidence in the
`
`4
`
`
`
`
`form of Japanese language exhibits (Ex. 1062-1065) purportedly from Mr.
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`Kawashima’s 2016 deposition. Paper 118 at 9. These exhibits were not filed with
`
`English translations, so they are inadmissible under 37 CFR 42.63(b). In any case,
`
`the 2016 deposition transcript does not include testimony putting to rest the
`
`deficiencies of the 2005 deposition. Instead, it once again suggests that Mr.
`
`Kawashima could not have examined the document in a way that would have
`
`differentiated it from any other version. Ex. 2163 at 45-46.
`
`As explained in TT’s motion, the 2016 deposition transcript also proves Mr.
`
`Kawashima’s bias. Paper 114 at 8. Petitioners argue that any alleged bias goes to
`
`the weight of the testimony, not to its admissibility. Paper 118 at 9-10. TT agrees.
`
`Mr. Kawashima’s bias goes to the weight that his testimony should be given. Mr.
`
`Kawashima’s testimony should be given no weight, so it cannot authenticate TSE.
`
`II. Expert Testimony
`As pointed out in TT’s motion, its experts’ answers to certain vague and
`
`ambiguous questions yielded irrelevant testimony that Petitioners are using in a
`
`confusing and misleading manner. Nothing in Petitioners’ opposition changes that.
`
`
`
`Respectfully Submitted,
`
`Date: October 14, 2016
`
`By:
`
`/Joshua L. Goldberg/ (Reg. No. 59,369)
`
`5
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`CBM2015-00179
`U.S. Patent 7,533,056
`
`The undersigned hereby certifies that a copy of the foregoing REPLY IN
`
`SUPPORT OF PATENT OWNER’S MOTION TO EXCLUDE UNDER 37
`
`C.F.R. 42.64(C) was served on October 14, 2016, via email directed to counsel of
`
`record for the Petitioners at the following:
`
`Robert E. Sokohl
`rsokohl-PTAB@skgf.com
`
`Lori Gordon
`lgordon-PTAB@skgf.com
`
`Richard M. Bemben
`rbemben-PTAB@skgf.com
`
`John C. Phillips
`CBM41919-0007CP1@fr.com
`
`PTAB@skgf.com
`
`
`Dated: October 14, 2016
`
`/Lisa C. Hines/
`Lisa C. Hines
`Litigation Clerk
`
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP